MedTrace Logo

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

NCT05601336 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-05-30

No results posted yet for this study

Summary

The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and dapagliflozin as monotherapies and the effect of both of them as a combined therapy in infertile women with PCOs.

Conditions

  • PCO

Interventions

DRUG

Dapagliflozin 5 MG

SGLT2 inhibitor

DRUG

Metformin Hydrochloride 1000 MG

metformin

DRUG

Dapagliflozin/Metformin

SGLT2 inhibitor and metformin HCl extended-release

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Beni-Suef University · Clinical Pharmacy Faculty of Pharmacy Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2023-07-30
Completion
2023-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05601336 on ClinicalTrials.gov